Argentina's Ministry of Health authorized bio-pharmaceutical company Mediwound Ltd. to market and distribute NexoBrid®, which removes dead or damaged tissue from adults with thermal burns, Thursday.
"We are delighted NexoBrid will soon be available to treat patients in Argentina who are afflicted with severe burns and who are mainly treated at a few specialized burn centers," Gal Cohen, president and CEO of MediWound, said. "This approval is in line with our strategy to expand the reach of NexoBrid to emerging markets with a focus in Latin America, Asia Pacific and CIS."
Clinical studies conducted on NexoBrid show that the product debrides burn wounds earlier than the current standard of care, significantly reducing the number and extent of surgical excisions and autografting.
NexoBrid also removes dead or damaged tissue in four hours without harming the surrounding healthy tissues and is now available commercially in Europe and Israel.
For more information, visit www.mediwound.com.
Organizations in this Story
Want to get notified whenever we write about MediWound Ltd ?
Next time we write about MediWound Ltd, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.Sign-up for Alerts
- Guatemalan businessman Fernando Jarquín implements vision for development
- Emiliano Salinas cuts ties with NXIVM
- Fernando Jarquin, Guatemala’s Pharmaceutical Innovator and Entrepreneur, Talks Business
- New Colombia Resources says Sannabis test was successful
- Grupo Exito aims to help support Colombia
- Codelco CEO calls for transparency, focus on production goals
- BCP offers tips on choosing master's degree program
- General Tire launches new tire for Andean market
- Latin America talks of boosting pork production, exports @CorferiasBogota
- AIR Worldwide team takes part in wind-engineering conference